BioPharma Dive January 9, 2023
Drugmakers will need to navigate a new drug pricing law in 2023, as well as regulatory shifts at the FDA and FTC.
The year ahead could be challenging for the pharmaceutical industry. 2023 will mark the rollout of significant drug pricing reforms in the U.S., put in motion by last year’s passage of the Inflation Reduction Act. Not to be undone by its rare defeat, the industry’s main lobbying group has promised to push back, setting up potential skirmishes over how the law will be implemented.
Regulatory clouds could form over M&A activity, which has recently picked up as larger companies race to plug revenue holes from expected patent expirations later this decade.
Finally, scrutiny of the Food and Drug...
Today's Sponsors
Today's Sponsor
Topics: Biotechnology, CMS, Congress / White House, FDA, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Regulations